Plant bio-factories contributing to the COVID-19 fight
Researchers have made the genome of the Nicotiana benthamiana plant, a commonly used bio-factory organism, public to aid in COVID-19 vaccine production.
List view / Grid view
Researchers have made the genome of the Nicotiana benthamiana plant, a commonly used bio-factory organism, public to aid in COVID-19 vaccine production.
Austrian researchers reveal the first 21 SARS-CoV-2 viral genomes as part of their project to aid in international understanding of how the virus causing COVID-19 mutates.
Chinese researchers who determined the crystal structure of the COVID-19 protease Mpro used this information to screen over 10,000 compounds to combat the coronavirus.
Researchers propose using mesenchymal stem cells to counter the pro-inflammatory cytokines associated with COVID-19 coronavirus symptoms.
Dr Kutschera discusses the differences between males and females in relation to infection from the COVID-19 coronavirus.
The developers of the lung epithelium model plan to investigate whether SARS-CoV-2 can infect and replicate in the model to assess whether it could be used in the fight against COVID-19.
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
Researchers working on related coronaviruses SARS and MERS have identified the membrane fusion peptide on the Spike protein as a possible drug target for SARS-CoV-2, the virus causing COVID-19.
The vaccine candidate protected all murine models from a lethal MERS infection and could also be effective against the SARS-CoV-2 virus causing COVID-19.
Sequencing almost 60,000 cells, researchers have found that certain cilia progenitor cells have gene transcripts for ACE2 and co-factor TMPRSS2, enabling COVID-19 infection.
A potential COVID-19 vaccine has been developed by researchers using AI and cloud computing to prevent the Spike protein from binding to the ACE2 receptor on human cells.
Collaborators have shown that the broad spectrum oral antiviral EIDD-2801 could be a potential prophylactic or therapeutic for COVID-19 and other coronaviruses.
The interaction between a SARS antibody called CR3022 and the COVID-19 coronavirus has been mapped by researchers, revealing a viral vulnerability.
Following the screening of antibodies, Celltrion will now identify the most potent out of 300 hits that work against the COVID-19 coronavirus best.
Two companies, Neurimmune and Ethris, will leverage their technologies to research, develop and produce an inhaled therapy for COVID-19.